Home » Stocks » EYPT

EyePoint Pharmaceuticals, Inc. (EYPT)

Stock Price: $0.430 USD 0.000 (0.07%)
Updated November 24, 1:04 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 61.75M
Revenue (ttm) 35.94M
Net Income (ttm) -40.34M
Shares Out 143.52M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $0.430
Previous Close $0.430
Change ($) 0.000
Change (%) 0.07%
Day's Open 0.421
Day's Range 0.415 - 0.432
Day's Volume 629,360
52-Week Range 0.351 - 2.100

More Stats

Market Cap 61.75M
Enterprise Value 86.14M
Earnings Date (est) Mar 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 143.52M
Float 97.27M
EPS (basic) -0.33
EPS (diluted) -0.34
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.36M
Short Ratio 1.28
Short % of Float 2.42%
Beta 1.22
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.72
PB Ratio 8.20
Revenue 35.94M
Operating Income -33.54M
Net Income -40.34M
Free Cash Flow -31.99M
Net Cash -24.38M
Net Cash / Share -0.17
Gross Margin 6.43%
Operating Margin -93.32%
Profit Margin -112.20%
FCF Margin -89.02%
ROA -26.42%
ROE -342.81%
ROIC -52.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.38*
(453.10% upside)
Low
0.50
Current: $0.430
High
5.00
Target: 2.38
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20.372.967.541.6226.573.472.143.534.9723.05
Revenue Growth587.77%-60.72%365.37%-93.9%664.9%62.06%-39.22%-28.98%-78.46%-
Gross Profit17.682.967.541.6226.573.472.143.534.9723.05
Operating Income-47.86-26.27-18.58-21.776.42-13.49-12.03-25.21-10.009.09
Net Income-56.79-53.17-18.49-21.556.35-13.36-11.90-24.84-8.638.75
Shares Outstanding10446.2335.3431.6229.3827.4423.0420.7919.4918.41
Earnings Per Share-0.54-1.15-0.52-0.680.21-0.49-0.52-1.19-0.440.46
Operating Cash Flow-56.70-21.91-20.49-16.3210.30-10.67-8.75-9.00-3.179.90
Capital Expenditures-0.21-0.11-0.11-0.11-0.16-0.17-0.07-0.41-0.13-0.02
Free Cash Flow-56.91-22.02-20.60-16.4310.14-10.84-8.81-9.41-3.309.88
Cash & Equivalents22.3638.9317.0529.1428.6918.4310.2714.5724.1317.57
Total Debt50.1217.31--------
Net Cash / Debt-27.7621.6217.0529.1428.6918.4310.2714.5724.1317.57
Assets72.9771.6718.6831.6232.3722.6716.2520.6047.1143.01
Liabilities64.6459.985.3410.749.007.758.556.969.689.97
Book Value8.3311.6913.3420.8823.3714.927.7013.6437.4333.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name EyePoint Pharmaceuticals, Inc.
Country United States
Employees 84
CEO Nancy Sue Lurker

Stock Information

Ticker Symbol EYPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EYPT
IPO Date January 27, 2005

Description

EyePoint Pharmaceuticals, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.